Hydrocephalus: Pathophysiology, Types, and Management

Normal CSF Physiology (Foundation)

Definition

• Robbins & Kumar Basic Pathology, p. 821
• Bradley and Daroff's Neurology in Clinical Practice, p. 1853

Pathophysiology

The Imbalance Mechanism

1. Obstruction to flow - either within the ventricular system (intraventricular) or within the subarachnoid space/arachnoid granulations
2. Decreased resorption - impaired arachnoid granulation function (post-hemorrhage, post-infection, venous hypertension)
3. Overproduction - rare; can occur with choroid plexus papilloma

Sequence of Events in Acute Hydrocephalus

1. Obstruction occurs → CSF continues to be produced despite rising pressure
2. 80% of maximal ventricular enlargement occurs within the first 6 hours of onset (acute phase)
3. A slower phase of further enlargement follows
4. CSF accumulates in the periventricular white matter interstitial space → transependymal edema (periventricular lucency on CT/MRI)
5. In the chronic phase, ventricular pressure may normalize due to compensatory drainage, even though structural damage persists
6. Long-standing hydrocephalus → white matter atrophy, axonal damage, subependymal gliosis

Classification / Types

1. Non-communicating Hydrocephalus (Obstructive/Intraventricular)

• Foramen of Monro - colloid cysts, suprasellar tumors, subependymal giant cell astrocytomas (in tuberous sclerosis)
• Cerebral aqueduct (of Sylvius) - most common site; aqueductal stenosis (congenital or post-infectious gliosis), tectal plate gliomas, pineal region tumors, brainstem diffuse astrocytomas
• Fourth ventricular outflow (foramina of Luschka and Magendie) - Dandy-Walker malformation, Chiari II malformation, posterior fossa tumors (medulloblastoma, ependymoma), cerebellar hemorrhage/infarction

• Temporal horn dilatation disproportionate to lateral ventricle size
• Anterior and posterior recess enlargement of the third ventricle
• Inferior convexity of the third ventricular floor
• Transependymal edema (periventricular hyperintensity)
• Sulcal spaces, basal cisterns effaced/obliterated

2. Communicating Hydrocephalus (Extraventricular Obstructive)

• Post-subarachnoid hemorrhage (blood products impair arachnoid granulation absorption)
• Post-meningitis (infectious scarring - bacterial, TB, fungal, syphilis)
• Leptomeningeal carcinomatosis
• Raised intracranial venous pressure (venous sinus thrombosis, dural AVMs, vein of Galen malformations, craniosynostosis with jugular foramen stenosis)
• Idiopathic (especially in elderly - NPH)

3. Normal Pressure Hydrocephalus (NPH)

• Gait disturbance - apraxic ("magnetic") gait; feet appear stuck to the floor; broad-based; frontal lobe pattern
• Urinary incontinence
• Dementia - subcortical type; psychomotor slowing, apathy, preserved language and spatial function

• CT/MRI: enlarged ventricles out of proportion to sulcal atrophy; transependymal edema
• LP tap test (large-volume removal of 30-50 mL CSF): temporary improvement in gait confirms likely shunt responsiveness; a 2025 systematic review (PMID 40045804) highlighted the need to standardize this test
• Continuous ICP monitoring (gold standard)
• Isotope cisternography (reflux of isotope into ventricles, delayed cortical clearance)

4. Hydrocephalus Ex Vacuo

5. Congenital / Pediatric Hydrocephalus

• Aqueductal stenosis - most common cause; can be developmental or acquired (post-IVH, post-infection)
• Chiari II malformation - associated with lumbosacral myelomeningocele; hindbrain herniation kinks the aqueduct
• Dandy-Walker malformation - cystic dilatation of the fourth ventricle, absent or hypoplastic vermis, obstructed foramina
• Post-hemorrhagic (germinal matrix IVH in premature infants <1500 g; ~25% develop progressive ventricular enlargement)
• Post-infective (TORCH infections, neonatal bacterial meningitis)
• Vein of Galen malformation - venous hypertension mechanism

Clinical Features by Age Group

Infants (sutures open, <2 years)

• Progressive macrocephaly (most reliable sign) - head circumference crossing centiles upward
• Frontal bossing, calvarial thinning
• Tense, bulging anterior fontanelle
• Sutural diastasis
• Enlarged scalp veins
• "Sunsetting" eyes - downward deviation of gaze from tectal compression (Parinaud's phenomenon)
• Lateral rectus palsy (CN VI false localizing sign)
• Lower limb spasticity (corticospinal tract stretching)
• Irritability, poor feeding, lethargy

Older Children (sutures fused)

• Early morning headache, nausea, vomiting
• Papilledema
• Diplopia (CN VI palsy)
• Ataxia (posterior fossa mass effect)
• Altered consciousness
• "Cracked pot" sound on skull percussion (McEwen sign)
• Endocrine dysfunction if third ventricle involved (growth failure, DI, amenorrhea)

Adults

• Acute: severe headache, papilledema, diplopia, mental status changes, sudden death (from severe ICP elevation)
• Subacute: progressive symptoms depending on site
• Colloid cyst of third ventricle: positional headaches with drop attacks (ball-valve effect - intermittent acute obstruction of foramen of Monro)
• Cerebellar hemorrhage/infarction: headache, ataxia, progressive drowsiness → acute obstructive hydrocephalus requiring emergency intervention

Imaging

Management

1. Emergency / Acute Measures

• External Ventricular Drain (EVD): First-line for acute hydrocephalus (post-SAH, cerebellar hemorrhage, meningitis); removes CSF and monitors ICP continuously. Many patients requiring EVD will eventually need a permanent shunt.
• Posterior fossa craniectomy: For cerebellar hemorrhage with brainstem compression - decompress mass + restore CSF flow; preceded by EVD catheter placement.
• Medical: Acetazolamide (carbonic anhydrase inhibitor, reduces CSF production) and furosemide used as temporizing measures in premature infants with post-hemorrhagic hydrocephalus; not curative.

2. Ventriculoperitoneal Shunt (VP Shunt) - Most Common Definitive Treatment

• Ventriculoatrial (VA) shunt - drains to right atrium; used when peritoneal placement is impossible
• Ventriculopleural shunt - less common; drains to pleural space

3. Endoscopic Third Ventriculostomy (ETV)

4. NPH-Specific Management

• Large-volume LP tap test (30-50 mL): if gait improves within 24-72 hours, VP shunt placement is likely to benefit the patient. Gait improvement predicts better prognosis than improvement in dementia alone.
• VP shunt is the primary treatment; patients with gait as the dominant presenting feature respond best.
• Optimal CSF pressure setting on the shunt valve requires careful titration to avoid over-drainage.
• A 2025 systematic review on cerebral blood flow and autoregulation in NPH (PMID 41402911) highlights impaired vascular reactivity as part of the NPH mechanism, informing future therapeutic targets.

5. Treatment of Underlying Cause

• Remove obstructing tumor/mass
• Treat meningitis (antibiotics/antifungals)
• Drain hematoma
• Repair vascular malformation

Summary Table

Anti-Edema Measures in Hydrocephalus

Conceptual Framework

1. Reduce CSF volume (drainage, reduce production)
2. Reduce brain water/edema (osmotherapy, corticosteroids)
3. Reduce cerebral blood volume (positioning, hyperventilation - temporary)

1. General / Supportive Measures (First-Line - Immediate)

• Adams and Victor's Principles of Neurology, 12th Ed., p. 913

2. Osmotic Therapy (Cornerstone of Medical Management)

A. Mannitol

• Dose: 0.25–1.0 g/kg IV as a 20% solution, every 3–6 hours
• Target: Serum osmolality 290–315 mOsm/L; serum sodium >142 mEq/L
• Ceiling: Do NOT exceed serum osmolality of 320 mOsm/kg (above this, efficacy falls and renal failure risk rises)
• Mechanism: Multiple actions - osmotic dehydration of brain, reduces CSF production, improves CBF by reducing blood viscosity
• Onset: Rapid; also has an immediate rheologic effect on blood viscosity before the osmotic effect is established
• Duration: 2-6 hours per dose
• Side effects:
  • Diuresis → hypovolemia, hypokalemia, hypernatremia
  • Renal failure (rare; mainly with >200 g/day; almost always reversible)
  • Rebound edema if discontinued abruptly (small-molecule diuretics like urea cause rebound; mannitol causes less, but still possible)
  • Hyperglycemic hyperosmolar state in diabetics
• Preferred when: Patient is fluid-overloaded or euvolemic; large-molecule, does not expand vascular volume

B. Hypertonic Saline (HTS)

• Formulations and doses:
  • 3% NaCl: bolus 150 mL, or continuous infusion 30–50 mL/hr
  • 7.5% NaCl: 75 mL boluses
  • 23.4% NaCl: 30 mL boluses (requires central venous access for all concentrations >3%)
• Target: Serum sodium up to 160 mEq/L (upper limit)
• Mechanism: Directly raises serum sodium and osmolality; expands intravascular volume (unlike mannitol, which diureses)
• Advantages over mannitol: No diuresis; can be used as a resuscitation fluid simultaneously; avoids hypovolemia; at least as effective as mannitol
• Disadvantages: Can cause volume overload/pulmonary edema in poor cardiac function; risk of osmotic demyelination if sodium correction too rapid; requires central line for concentrated formulations
• Preferred when: Patient is hypovolemic, hypotensive, or requires fluid resuscitation; also when mannitol has caused excessive diuresis

"Several small series comparing the agents have shown too little difference to allow a choice between the two agents. Local experience and an overall assessment of side effects typically dominate practice." - Adams and Victor's Principles of Neurology, p. 913-914

3. Reduction of CSF Production

Acetazolamide (Carbonic Anhydrase Inhibitor)

• Mechanism: Inhibits carbonic anhydrase in the choroid plexus → reduces Na⁺/H⁺ exchange → reduces CSF secretion by ~50%
• Use: Primary medical treatment for slowly progressive hydrocephalus and as a bridge to surgery; also used in idiopathic intracranial hypertension (pseudotumor cerebri)
• Dose (adults): 250 mg–1 g orally 2–4 times daily (typically up to 2 g/day)
• Dose (pediatric/neonates): Used combined with furosemide for post-hemorrhagic hydrocephalus in premature infants
• Limitations: "Of marginal benefit" as a standalone agent; does not address the obstruction; not suitable for acute presentations
• Side effects: Metabolic acidosis, hypokalemia, paresthesias, nephrolithiasis, sulfa allergy cross-reactivity

Furosemide (Loop Diuretic)

• Mechanism: Inhibits Na-K-2Cl cotransporter in choroid plexus; also independent systemic diuresis reduces brain interstitial water
• Use: Used in combination with acetazolamide (synergistic); especially in neonatal/pediatric progressive hydrocephalus as a temporizing measure
• Limitation: Not definitive; primarily a bridge to surgical management

"Acetazolamide and furosemide may provide temporary relief by decreasing the rate of CSF production [in slowly progressive hydrocephalus]." - The Harriet Lane Handbook, 23rd Ed., p. 731

4. Reduction of Cerebral Blood Volume

Controlled Hyperventilation

• Mechanism: Lowering PaCO₂ → CSF alkalosis → cerebral vasoconstriction → ↓cerebral blood volume → ↓ICP
• Target: PaCO₂ 30–35 mmHg (mild hyperventilation); avoid <25 mmHg
• Onset: Rapid (minutes); effect lasts only 20–40 minutes - pH equilibrates as choroid plexus generates ammonium buffers
• Use: Emergency bridge only - acute herniation, acute ICP spike, while surgical intervention is being prepared
• Caution: Excessive hyperventilation can cause cerebral ischemia (vasoconstriction reduces perfusion); particularly dangerous in children - even modest hypocarbia (PCO₂ <25 mmHg) shows ischemic changes in 75% of pediatric patients
• NOT for chronic use - loss of effect, risk of ischemia
• Adams and Victor's Principles of Neurology, p. 914
• Bradley and Daroff's Neurology in Clinical Practice, p. 1851

5. Corticosteroids

• Mechanism: Reduce vasogenic edema by stabilizing and restoring the blood-brain barrier permeability; reduce release of vasogenic cytokines
• Dexamethasone is the agent of choice (best CNS penetration, minimal mineralocorticoid effect)
  • Standard dose: 4–10 mg IV loading, then 4 mg every 6 hours
  • High-dose: up to 100 mg/day in severe cases

• Peritumoral vasogenic edema (brain tumors, metastases) - dramatic and rapid response; reduces edema around tumor causing the obstruction
• Inflammatory/demyelinating causes (MS lesions blocking CSF pathways) - high-dose methylprednisolone 1 g/day x 3–5 days
• Bacterial meningitis - dexamethasone reduces neuroinflammation and risk of post-meningitic communicating hydrocephalus (adjunct to antibiotics)
• Spinal cord edema post-surgically

• Traumatic brain injury - the CRASH trial (>10,000 patients) showed methylprednisolone significantly increased mortality vs. placebo; absolutely contraindicated
• Cytotoxic edema (ischemic stroke, intracerebral hemorrhage) - no benefit; systemic complications worsen outcome
• Pure obstructive hydrocephalus without vasogenic edema - no direct benefit; may mask signs of infection

"Corticosteroids lower ICP primarily in vasogenic edema... they have been less effective in cytotoxic edema, and are contraindicated in the treatment of edema secondary to stroke or hemorrhage." - Bradley and Daroff's Neurology in Clinical Practice, p. 1852

6. Sedation and Analgesia for ICP Control

• Propofol: First-choice IV sedative in ICU; decreases cerebral metabolic rate, oxygen demand, and CBF; rapidly clears for neurologic assessment; watch for hypotension
• Dexmedetomidine: Alternative; preserves neurologic exam; risk of hypotension and bradycardia; does not suppress respiratory drive
• Barbiturate coma (pentobarbital):
  • Loading dose: 10 mg/kg IV over 30 minutes
  • Maintenance: 1–4 mg/kg/hour, titrated to EEG burst suppression
  • Reserved for refractory ICP (>40 mmHg) unresponsive to all other measures
  • Major drawback: hypotension requiring vasopressors; significantly reduces cerebral perfusion pressure
  • Evidence shows no overall outcome benefit; used only as last resort before decompressive craniectomy
• Rosen's Emergency Medicine, p. 70

7. Hypothermia

• Mechanism: Reduces cerebral metabolic demand and CBF
• Target temperature: 32–34°C
• Current evidence: Multiple RCTs (DECRA, RESCUEicp, Clifton, Andrews) have failed to show improved outcomes. Major problem: rebound ICP surge on rewarming. Not routinely recommended; may be used in very selected cases with refractory ICP.

8. Decompressive Craniectomy

• The surgical last resort for medically refractory intracranial hypertension
• Removes a large bone flap to allow brain to expand without herniation
• ICP monitoring is required to trigger this decision (persistent ICP >25 mmHg despite all medical measures)
• Evidence from RESCUEicp trial: reduces mortality but increases survivors with severe disability

Step-Wise Protocol Summary

STEP 1 (Immediate - all patients)
  → Head 30° elevation, correct hypoxia, hypercarbia, fever
  → Isotonic/hypertonic fluids ONLY; avoid hypotonic solutions
  → Adequate analgesia/sedation (propofol + fentanyl)

STEP 2 (Pharmacological)
  → Acute/symptomatic: Mannitol 0.25-1 g/kg IV or HTS bolus
  → Subacute/progressive: Acetazolamide ± furosemide (reduces CSF production)
  → Vasogenic edema (tumor/inflammation): Dexamethasone 4-10 mg IV
  → Emergency bridge: Controlled hyperventilation PaCO₂ 30-35 mmHg

STEP 3 (Refractory ICP)
  → Barbiturate coma (pentobarbital)
  → Therapeutic hypothermia (selected cases)

STEP 4 (Definitive)
  → CSF drainage: EVD, VP shunt, or ETV
  → Decompressive craniectomy (last resort)

Key Distinctions by Edema Type